marketcaparena
Search

    AVLN

    Avalyn Pharma Inc.

    Company overview

    Market capitalization
    $1.26B
    Employees
    50
    Latest publication
    2026-09-29
    About Avalyn Pharma Inc.

    Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. The company provides inhaled formulations of oral medicines directly to the lungs. Its current pipeline is focused on treating pulmonary fibrosis. Its products include AP01 and AP02, inhaled formulations of pirfenidone and nintedanib for the treatment of progressive pulmonary fibrosis and idiopathic pulmonary fibrosis; and AP03, a fixed-dose combination of inhaled pirfenidone and nintedanib to deliver dual antifibrotic mechanisms. Avalyn Pharma Inc. was formerly known as Genoa Pharmaceuticals, Inc. and changed its name to Avalyn Pharma Inc. in July 2017. The company was incorporated in 2011 and is based in Boston, Massachusetts.

    Company website

    Financial statements

    Income Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USD
    Total Revenue0USD0USD
    Research Development76,614,000USD45,759,000USD
    Selling General Administrative14,678,000USD11,362,000USD
    Total Operating Expenses91,292,000USD57,121,000USD
    Operating Income-91,292,000USD-57,121,000USD
    Interest Income6,177,000USD7,439,000USD
    Net Interest Income6,177,000USD7,439,000USD
    Income Before Tax-85,204,000USD-49,744,000USD
    Net Income-85,204,000USD-49,744,000USD
    Net Income From Continuing Ops-85,204,000USD-49,744,000USD
    Reconciled Depreciation42,000USD29,000USD
    Total Other Income Expense Net-89,000USD-62,000USD
    SourceLegacy providerLegacyLegacy providerLegacy

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USD
    Total Assets425,448,000USD
    Cash And Equivalents264,197,000USD
    Cash And Short Term Investments352,425,000USD
    Short Term Investments88,228,000USD
    Long Term Investments61,103,000USD
    Total Current Assets357,988,000USD
    Other Current Assets5,563,000USD
    Other Non Current Assets3,011,000USD
    Total Liabilities27,102,000USD
    Total Current Liabilities10,809,000USD
    Other Current Liabilities7,345,000USD
    Total Stockholder Equity398,346,000USD
    Total Equity Including Noncontrolling Interest398,346,000USD
    Long Term Debt14,801,000USD
    Property Plant Equipment Net3,346,000USD
    Accounts Payable2,648,000USD
    Short Term Debt816,000USD
    Common Stock67,000USD
    Retained Earnings-321,167,000USD
    Accumulated Other Comprehensive Income-95,000USD
    SourceDisclosureDeterministicFinal

    Balance sheet Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USD
    Total Assets148,881,000USD124,519,000USD
    Total Liab387,537,000USD299,041,000USD
    Total Stockholder Equity-238,656,000USD-174,522,000USD
    Capital Stock24,000USD5,000USD
    Retained Earnings-265,362,000USD-180,158,000USD
    Cash52,315,000USD23,955,000USD
    Total Current Assets143,560,000USD114,387,000USD
    Total Current Liabilities14,091,000USD8,744,000USD
    Long Term Investments0USD7,489,000USD
    Short Term Investments86,044,000USD86,671,000USD
    Accounts Payable3,758,000USD2,277,000USD
    Property Plant Equipment Net2,322,000USD94,000USD
    Property Plant Equipment Gross2,376,000USD106,000USD
    Common Stock Shares Outstanding41,812,047shares41,812,047shares
    Non Current Assets Total5,321,000USD10,132,000USD
    Non Current Liabilities Total373,446,000USD290,297,000USD
    Non Currrent Assets Other2,999,000USD2,549,000USD
    Net Working Capital129,469,000USD105,643,000USD
    Unclassified Current Assets5,201,000USD3,761,000USD
    Unclassified Current Liabilities10,333,000USD6,467,000USD
    Unclassified Non Current Liabilities373,446,000USD290,297,000USD
    Unclassified Equity26,682,000USD5,631,000USD
    SourceLegacy providerLegacyLegacy providerLegacy

    Cash flow Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USD
    Net Income-85,204,000USD-49,744,000USD
    Depreciation42,000USD29,000USD
    Stock Based Compensation3,274,000USD2,471,000USD
    Other Non Cash Items146,000USD50,000USD
    Change In Working Capital2,611,000USD1,360,000USD
    Total Cash From Operating Activities-81,484,000USD-48,368,000USD
    Capital Expenditures-344,000USD-95,000USD
    Free Cash Flow-81,828,000USD-48,463,000USD
    Investments10,401,000USD-91,379,000USD
    Total Cash From Financing Activities99,787,000USD89,000USD
    Issuance Of Capital Stock100,363,000USD0USD
    Change In Cash28,360,000USD-139,753,000USD
    Begin Period Cash Flow23,955,000USD163,708,000USD
    End Period Cash Flow52,315,000USD23,955,000USD
    Unclassified Operating Cash Flow-2,353,000USD-2,534,000USD
    SourceLegacy providerLegacyLegacy providerLegacy

    Operating metrics

    No operating metrics are currently published for this company.

    Revenue breakdown

    No revenue breakdown is currently published for this company.

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.